Non-viral delivery of RNA for therapeutic T cell engineering
Advanced Drug Delivery Reviews · 2024-05 · 208 · 115215
DOI: 10.1016/j.addr.2024.115215 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2024-05. Verfasst von Dominika Berdecka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, B…. Hauptthemen laut MEDLINE: T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 346 Literaturangaben.
Abstract (Originalsprache)
Adoptive T cell transfer has shown great success in treating blood cancers, resulting in a growing number of FDA-approved therapies using chimeric antigen receptor (CAR)-engineered T cells. However, the effectiveness of this treatment for solid tumors is still not satisfactory, emphasizing the need for improved T cell engineering strategies and combination approaches. Currently, CAR T cells are mainly manufactured using gammaretroviral and lentiviral vectors due to their high transduction efficiency. However, there are concerns about their safety, the high cost of producing them in compliance with current Good Manufacturing Practices (cGMP), regulatory obstacles, and limited cargo capacity, which limit the broader use of engineered T cell therapies. To overcome these limitations, researchers have explored non-viral approaches, such as membrane permeabilization and carrier-mediated methods, as more versatile and sustainable alternatives for next-generation T cell engineering. Non-viral delivery methods can be designed to transport a wide range of molecules, including RNA, which allows for more controlled and safe modulation of T cell phenotype and function. In this review, we provide an overview of non-viral RNA delivery in adoptive T cell therapy. We first define the different types of RNA therapeutics, highlighting recent advancements in manufacturing for their therapeutic use. We then discuss the challenges associated with achieving effective RNA delivery in T cells. Next, we provide an overview of current and emerging technologies for delivering RNA into T cells. Finally, we discuss ongoing preclinical and clinical studies involving RNA-modified T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Laboratory of Cell Biology and Histology, Department of Veteri…
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
- Laboratory of Cell Biology and Histology, Department of Veterinary Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium. Electronic address: Kevin.Braeckmans@ugent.be.
Zitieren
APA
Berdecka, D., De Smedt, S. C., De Vos, W. H., & Braeckmans, K. (2024). Non-viral delivery of RNA for therapeutic T cell engineering. Advanced Drug Delivery Reviews, 208, 115215. https://doi.org/10.1016/j.addr.2024.115215
Vancouver
Berdecka D, De Smedt SC, De Vos WH, Braeckmans K. Non-viral delivery of RNA for therapeutic T cell engineering. Advanced Drug Delivery Reviews. 2024;208:115215. doi:10.1016/j.addr.2024.115215
BibTeX
@article{Berdecka2024,
author = {Berdecka, Dominika and De Smedt, Stefaan C and De Vos, Winnok H and Braeckmans, Kevin},
title = {Non-viral delivery of RNA for therapeutic T cell engineering},
journal = {Advanced Drug Delivery Reviews},
year = {2024},
volume = {208},
pages = {115215},
doi = {10.1016/j.addr.2024.115215}
}
EUVIMED